Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BLTE NASDAQ:IDYA NASDAQ:OCUL NASDAQ:ORKA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLTEBelite Bio$69.16+3.4%$65.13$43.70▼$86.53$2.20B-1.543,687 shs17,246 shsIDYAIDEAYA Biosciences$24.80+0.3%$24.08$13.45▼$36.70$2.17B0.121.15 million shs289,961 shsOCULOcular Therapeutix$12.35-0.7%$12.14$5.78▼$13.85$2.16B1.51.85 million shs594,622 shsORKAOruka Therapeutics$16.05+7.7%$14.69$5.49▼$31.13$603.32M-0.26243,103 shs1.33 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLTEBelite Bio+0.15%+1.86%+0.41%+10.83%+37.34%IDYAIDEAYA Biosciences+0.77%-0.08%+1.60%+13.08%-32.88%OCULOcular Therapeutix-0.80%-2.51%-1.43%+49.34%+39.31%ORKAOruka Therapeutics-2.36%-7.17%-3.06%+24.37%-42.47%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLTEBelite Bio$69.16+3.4%$65.13$43.70▼$86.53$2.20B-1.543,687 shs17,246 shsIDYAIDEAYA Biosciences$24.80+0.3%$24.08$13.45▼$36.70$2.17B0.121.15 million shs289,961 shsOCULOcular Therapeutix$12.35-0.7%$12.14$5.78▼$13.85$2.16B1.51.85 million shs594,622 shsORKAOruka Therapeutics$16.05+7.7%$14.69$5.49▼$31.13$603.32M-0.26243,103 shs1.33 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLTEBelite Bio+0.15%+1.86%+0.41%+10.83%+37.34%IDYAIDEAYA Biosciences+0.77%-0.08%+1.60%+13.08%-32.88%OCULOcular Therapeutix-0.80%-2.51%-1.43%+49.34%+39.31%ORKAOruka Therapeutics-2.36%-7.17%-3.06%+24.37%-42.47%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLTEBelite Bio 3.00Buy$96.0042.23% UpsideIDYAIDEAYA Biosciences 2.81Moderate Buy$42.8571.71% UpsideOCULOcular Therapeutix 3.00Buy$17.8341.37% UpsideORKAOruka Therapeutics 3.20Buy$39.60134.95% UpsideCurrent Analyst Ratings BreakdownLatest ORKA, OCUL, IDYA, and BLTE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/15/2025BLTEBelite BioHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$100.00 ➝ $98.009/15/2025OCULOcular TherapeutixChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$21.009/12/2025IDYAIDEAYA BiosciencesMizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$43.00 ➝ $44.009/9/2025IDYAIDEAYA BiosciencesCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy9/9/2025IDYAIDEAYA BiosciencesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$36.00 ➝ $38.009/9/2025IDYAIDEAYA BiosciencesStephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$45.009/9/2025IDYAIDEAYA BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight9/8/2025IDYAIDEAYA BiosciencesOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOutperform$36.009/4/2025IDYAIDEAYA BiosciencesCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy ➝ Outperform9/4/2025IDYAIDEAYA BiosciencesJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Outperform$41.009/4/2025IDYAIDEAYA BiosciencesBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$40.00(Data available from 9/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLTEBelite BioN/AN/AN/AN/A$4.72 per shareN/AIDYAIDEAYA Biosciences$7M312.41N/AN/A$12.25 per share2.04OCULOcular Therapeutix$63.72M34.45N/AN/A$2.01 per share6.28ORKAOruka TherapeuticsN/AN/AN/AN/A$10.84 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLTEBelite Bio-$36.14M-$1.55N/AN/AN/AN/A-34.90%-33.56%11/11/2025 (Estimated)IDYAIDEAYA Biosciences-$274.48M-$3.79N/AN/AN/AN/A-31.42%-29.45%11/3/2025 (Estimated)OCULOcular Therapeutix-$193.51M-$1.28N/AN/AN/A-382.51%-71.92%-49.36%11/13/2025 (Estimated)ORKAOruka Therapeutics-$83.72M-$2.81N/AN/AN/AN/A-26.26%-24.16%11/12/2025 (Estimated)Latest ORKA, OCUL, IDYA, and BLTE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025BLTEBelite Bio-$0.47-$0.50-$0.03-$0.50N/AN/A8/11/2025Q1 2025ORKAOruka Therapeutics-$0.48-$0.46+$0.02-$0.46N/AN/A8/5/2025Q2 2025IDYAIDEAYA Biosciences-$0.85-$0.88-$0.03-$0.88$3.48 million$6.00 million8/5/2025Q2 2025OCULOcular Therapeutix-$0.35-$0.39-$0.04-$0.39$13.12 million$13.46 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLTEBelite BioN/AN/AN/AN/AN/AIDYAIDEAYA BiosciencesN/AN/AN/AN/AN/AOCULOcular TherapeutixN/AN/AN/AN/AN/AORKAOruka TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLTEBelite BioN/A23.1523.15IDYAIDEAYA BiosciencesN/A12.3912.39OCULOcular Therapeutix0.2310.1010.02ORKAOruka TherapeuticsN/A27.4227.42Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLTEBelite Bio0.53%IDYAIDEAYA Biosciences98.29%OCULOcular Therapeutix59.21%ORKAOruka Therapeutics56.44%Insider OwnershipCompanyInsider OwnershipBLTEBelite Bio13.29%IDYAIDEAYA Biosciences2.50%OCULOcular Therapeutix2.30%ORKAOruka Therapeutics24.69%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLTEBelite Bio1031.84 million27.61 millionNot OptionableIDYAIDEAYA Biosciences8087.64 million85.45 millionOptionableOCULOcular Therapeutix230173.99 million169.99 millionOptionableORKAOruka TherapeuticsN/A37.45 million28.20 millionN/AORKA, OCUL, IDYA, and BLTE HeadlinesRecent News About These CompaniesOruka Therapeutics Secures $180 Million in PIPE Financing to Advance Chronic Skin Disease TreatmentsSeptember 17 at 2:11 AM | quiverquant.comQOruka Therapeutics Announces $180 Million Private PlacementSeptember 17 at 2:02 AM | globenewswire.comOruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001September 17 at 2:00 AM | globenewswire.comOruka Therapeutics (NASDAQ:ORKA) Stock Price Down 5.4% - Here's What HappenedSeptember 14 at 3:40 PM | marketbeat.comBrokerages Set Oruka Therapeutics, Inc. (NASDAQ:ORKA) Price Target at $40.38September 6, 2025 | americanbankingnews.comOMERS ADMINISTRATION Corp Has $461,000 Holdings in Oruka Therapeutics, Inc. $ORKASeptember 5, 2025 | marketbeat.comOruka Therapeutics (NASDAQ:ORKA) Shares Up 6.6% - Time to Buy?September 4, 2025 | marketbeat.comADAR1 Capital Management LLC Purchases Shares of 132,780 Oruka Therapeutics, Inc. $ORKASeptember 4, 2025 | marketbeat.comRedmile Group LLC Cuts Position in Oruka Therapeutics, Inc. $ORKASeptember 4, 2025 | marketbeat.comOruka Therapeutics, Inc. (NASDAQ:ORKA) Given Consensus Recommendation of "Buy" by BrokeragesSeptember 4, 2025 | marketbeat.comBraidwell LP Raises Stake in Oruka Therapeutics, Inc. $ORKASeptember 3, 2025 | marketbeat.comOruka Therapeutics, Inc. $ORKA Shares Bought by Affinity Asset Advisors LLCAugust 28, 2025 | marketbeat.comOruka Therapeutics (NASDAQ:ORKA) Stock Price Down 5.8% - What's Next?August 27, 2025 | marketbeat.comCandriam S.C.A. Purchases Shares of 116,698 Oruka Therapeutics, Inc. $ORKAAugust 26, 2025 | marketbeat.comQ3 EPS Forecast for Oruka Therapeutics Decreased by AnalystAugust 22, 2025 | marketbeat.comOruka Therapeutics initiated with a Buy at Clear StreetAugust 21, 2025 | msn.comOruka Therapeutics (NASDAQ:ORKA) Earns Buy Rating from HC WainwrightAugust 20, 2025 | marketbeat.comOruka Therapeutics (ORKA) Receives a Buy from H.C. WainwrightAugust 19, 2025 | theglobeandmail.comWedbush Forecasts Reduced Earnings for Oruka TherapeuticsAugust 17, 2025 | marketbeat.comOruka Therapeutics (NASDAQ:ORKA) Downgraded by Wall Street Zen to "Sell"August 17, 2025 | marketbeat.comOruka Therapeutics (NASDAQ:ORKA) Is In A Good Position To Deliver On Growth PlansAugust 15, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeORKA, OCUL, IDYA, and BLTE Company DescriptionsBelite Bio NASDAQ:BLTE$69.38 +2.48 (+3.71%) As of 01:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.IDEAYA Biosciences NASDAQ:IDYA$24.77 +0.05 (+0.19%) As of 01:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Ocular Therapeutix NASDAQ:OCUL$12.35 -0.09 (-0.72%) As of 01:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.Oruka Therapeutics NASDAQ:ORKA$16.05 +1.15 (+7.72%) As of 01:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Hits Record High After CEO Hock Tan AI Pay Package CrowdStrike Stock Set for Breakout as Agentic AI Demand Surges Why CoreWeave's NVIDIA Deal Creates a Deep Moat for AI Investors Resideo Technologies: Institutional Activity Signals 30% Upside This Stock Quietly Benefits From Oracle and NVIDIA’s AI Surge Rezolute Stock: FDA Fast Track Fuels 2025 Breakout Lululemon’s Sell-Off Looks Overdone: A Contrarian Case This Defense Stock Is Up 113% This Year—Is It Still a Buy? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
